{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T20:41:05Z","timestamp":1792874465082,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T00:00:00Z","timestamp":1518134400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s00432-018-2600-1","type":"journal-article","created":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T14:30:13Z","timestamp":1518186613000},"page":"809-819","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Treatment with 5-azacitidine delay growth of glioblastoma xenografts: a potential new treatment approach for glioblastomas"],"prefix":"10.1007","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3996-0418","authenticated-orcid":false,"given":"Tobias","family":"Kratzsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne Antje","family":"Kuhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Joedicke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe Karsten","family":"Hanisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Vajkoczy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iduna","family":"Fichtner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,9]]},"reference":[{"key":"2600_CR40","doi-asserted-by":"crossref","unstructured":"(2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216):1061\u20131068","DOI":"10.1038\/nature07385"},{"issue":"2","key":"2600_CR1","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s00401-005-1041-5","volume":"110","author":"VJ Amatya","year":"2005","unstructured":"Amatya VJ, Naumann U, Weller M, Ohgaki H (2005) TP53 promoter methylation in human gliomas. Acta Neuropathol 110(2):178\u2013184","journal-title":"Acta Neuropathol"},{"issue":"2","key":"2600_CR2","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1517\/13543784.2014.856880","volume":"23","author":"I Arrillaga-Romany","year":"2014","unstructured":"Arrillaga-Romany I, Reardon DA, Wen PY (2014) Current status of antiangiogenic therapies for glioblastomas. Expert Opin Investig Drugs 23(2):199\u2013210","journal-title":"Expert Opin Investig Drugs"},{"issue":"5","key":"2600_CR3","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00401-003-0748-4","volume":"106","author":"N Baeza","year":"2003","unstructured":"Baeza N, Weller M, Yonekawa Y, Kleihues P, Ohgaki H (2003) PTEN methylation and expression in glioblastomas. Acta Neuropathol 106(5):479\u2013485","journal-title":"Acta Neuropathol"},{"issue":"4","key":"2600_CR4","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.mam.2012.06.007","volume":"34","author":"H Caren","year":"2013","unstructured":"Caren H, Pollard SM, Beck S (2013) The good, the bad and the ugly: epigenetic mechanisms in glioblastoma. Mol Aspects Med 34(4):849\u2013862","journal-title":"Mol Aspects Med"},{"key":"2600_CR5","doi-asserted-by":"crossref","unstructured":"Clarke J, Penas C, Pastori C, Komotar RJ, Bregy A, Shah AH, Wahlestedt C, Ayad NG (2013) Epigenetic pathways and glioblastoma treatment. Epigenetics 8(8):785\u2013795","DOI":"10.4161\/epi.25440"},{"key":"2600_CR6","unstructured":"Comprehensive IG (2015) Analysis of diffuse lower-grade gliomas. N Engl J Med"},{"issue":"4","key":"2600_CR7","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/S0021-9258(19)68144-5","volume":"257","author":"F Creusot","year":"1982","unstructured":"Creusot F, Acs G, Christman JK (1982) Inhibition of DNA methyltransferase and induction of friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2\u2032-deoxycytidine. J Biol Chem 257(4):2041\u20132048","journal-title":"J Biol Chem"},{"issue":"5792","key":"2600_CR8","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/288724a0","volume":"288","author":"RS Day 3rd","year":"1980","unstructured":"Day RS 3rd, Ziolkowski CH, Scudiero DA et al (1980) Defective repair of alkylated DNA by human tumour and SV40-transformed human cell strains. Nature 288(5792):724\u2013727","journal-title":"Nature"},{"issue":"3","key":"2600_CR9","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ctrv.2007.11.003","volume":"34","author":"A Duenas-Gonzalez","year":"2008","unstructured":"Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E, Herrera LA (2008) Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treatm Rev 34(3):206\u2013222","journal-title":"Cancer Treatm Rev"},{"key":"2600_CR10","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1186\/1471-2164-11-701","volume":"11","author":"A Etcheverry","year":"2010","unstructured":"Etcheverry A, Aubry M, de Tayrac M et al (2010) DNA methylation in glioblastoma: impact on gene expression and clinical outcome. BMC Genom 11:701","journal-title":"BMC Genom"},{"issue":"8","key":"2600_CR11","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1200\/JCO.2003.05.063","volume":"21","author":"A Giese","year":"2003","unstructured":"Giese A, Bjerkvig R, Berens ME, Westphal M (2003) Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 21(8):1624\u20131636","journal-title":"J Clin Oncol"},{"issue":"24","key":"2600_CR12","doi-asserted-by":"publisher","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","volume":"20","author":"M Gottlicher","year":"2001","unstructured":"Gottlicher M, Minucci S, Zhu P et al (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20(24):6969\u20136978","journal-title":"EMBO J"},{"issue":"10","key":"2600_CR13","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997\u20131003","journal-title":"N Engl J Med"},{"issue":"12","key":"2600_CR14","doi-asserted-by":"publisher","first-page":"3938","DOI":"10.1158\/1078-0432.CCR-08-2783","volume":"15","author":"JP Issa","year":"2009","unstructured":"Issa JP, Kantarjian HM (2009) Targeting DNA methylation. Clin Cancer Res 15(12):3938\u20133946","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2600_CR15","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nrg816","volume":"3","author":"PA Jones","year":"2002","unstructured":"Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3(6):415\u2013428","journal-title":"Nat Rev Genet"},{"issue":"1","key":"2600_CR16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/0092-8674(80)90237-8","volume":"20","author":"PA Jones","year":"1980","unstructured":"Jones PA, Taylor SM (1980) Cellular differentiation, cytidine analogs and DNA methylation. Cell 20(1):85\u201393","journal-title":"Cell"},{"issue":"3","key":"2600_CR17","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/glia.440150303","volume":"15","author":"P Kleihues","year":"1995","unstructured":"Kleihues P, Soylemezoglu F, Schauble B, Scheithauer BW, Burger PC (1995) Histopathology, classification, and grading of gliomas. Glia 15(3):211\u2013221","journal-title":"Glia"},{"issue":"4","key":"2600_CR18","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.cell.2007.02.005","volume":"128","author":"T Kouzarides","year":"2007","unstructured":"Kouzarides T (2007) Chromatin modifications and their function. Cell 128(4):693\u2013705","journal-title":"Cell"},{"issue":"6822","key":"2600_CR19","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/35057062","volume":"409","author":"ES Lander","year":"2001","unstructured":"Lander ES, Linton LM, Birren B et al (2001) Initial sequencing and analysis of the human genome. Nature 409(6822):860\u2013921","journal-title":"Nature"},{"issue":"4","key":"2600_CR20","doi-asserted-by":"publisher","first-page":"255","DOI":"10.4161\/epi.9130","volume":"4","author":"R Martinez","year":"2009","unstructured":"Martinez R, Martin-Subero JI, Rohde V et al (2009) A microarray-based DNA methylation study of glioblastoma multiforme. Epigenetics 4(4):255\u2013264","journal-title":"Epigenetics"},{"issue":"11","key":"2600_CR21","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1056\/NEJM199209103271104","volume":"327","author":"RH Mattson","year":"1992","unstructured":"Mattson RH, Cramer JA, Collins JF (1992) A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N Engl J Med 327(11):765\u2013771","journal-title":"N Engl J Med"},{"issue":"6","key":"2600_CR22","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1111\/j.1349-7006.2010.01545.x","volume":"101","author":"A Natsume","year":"2010","unstructured":"Natsume A, Kondo Y, Ito M, Motomura K, Wakabayashi T, Yoshida J (2010) Epigenetic aberrations and therapeutic implications in gliomas. Cancer Sci 101(6):1331\u20131336","journal-title":"Cancer Sci"},{"issue":"2","key":"2600_CR23","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.canlet.2015.01.005","volume":"359","author":"X Ning","year":"2015","unstructured":"Ning X, Shi Z, Liu X et al (2015) DNMT1 and EZH2 mediated methylation silences the microRNA-200b\/a\/429 gene and promotes tumor progression. Cancer Lett 359(2):198\u2013205","journal-title":"Cancer Lett"},{"issue":"10","key":"2600_CR24","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1212\/01.wnl.0000304121.57857.38","volume":"70","author":"AD Norden","year":"2008","unstructured":"Norden AD, Young GS, Setayesh K et al (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70(10):779\u2013787","journal-title":"Neurology"},{"issue":"1","key":"2600_CR25","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00401-005-0991-y","volume":"109","author":"H Ohgaki","year":"2005","unstructured":"Ohgaki H, Kleihues P (2005) Epidemiology and etiology of gliomas. Acta Neuropathol 109(1):93\u2013108","journal-title":"Acta Neuropathol"},{"issue":"21","key":"2600_CR26","doi-asserted-by":"publisher","first-page":"5952","DOI":"10.1158\/1078-0432.CCR-12-3588","volume":"19","author":"K Okemoto","year":"2013","unstructured":"Okemoto K, Kasai K, Wagner B et al (2013) DNA demethylating agents synergize with oncolytic HSV1 against malignant gliomas. Clin Cancer Res 19(21):5952\u20135959","journal-title":"Clin Cancer Res"},{"issue":"5897","key":"2600_CR27","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1126\/science.1164382","volume":"321","author":"DW Parsons","year":"2008","unstructured":"Parsons DW, Jones S, Zhang X et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321(5897):1807\u20131812","journal-title":"Science"},{"issue":"7","key":"2600_CR28","first-page":"2935","volume":"32","author":"J Polivka Jr","year":"2012","unstructured":"Polivka J Jr, Polivka J, Rohan V, Topolcan O, Ferda J (2012) New molecularly targeted therapies for glioblastoma multiforme. Anticancer Res 32(7):2935\u20132946","journal-title":"Anticancer Res"},{"issue":"8","key":"2600_CR29","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrg1655","volume":"6","author":"KD Robertson","year":"2005","unstructured":"Robertson KD (2005) DNA methylation and human disease. Nat Rev Genet 6(8):597\u2013610","journal-title":"Nat Rev Genet"},{"issue":"10","key":"2600_CR30","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","volume":"20","author":"LR Silverman","year":"2002","unstructured":"Silverman LR, Demakos EP, Peterson BL et al (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20(10):2429\u20132440","journal-title":"J Clin Oncol"},{"issue":"7","key":"2600_CR31","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1182\/blood-2007-03-078576","volume":"110","author":"AO Soriano","year":"2007","unstructured":"Soriano AO, Yang H, Faderl S et al (2007) Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 110(7):2302\u20132308","journal-title":"Blood"},{"issue":"1","key":"2600_CR32","doi-asserted-by":"publisher","first-page":"e87136","DOI":"10.1371\/journal.pone.0087136","volume":"9","author":"E Stoczynska-Fidelus","year":"2014","unstructured":"Stoczynska-Fidelus E, Piaskowski S, Bienkowski M et al (2014) The failure in the stabilization of glioblastoma-derived cell lines: spontaneous in vitro senescence as the main culprit. PLoS One 9(1):e87136","journal-title":"PLoS One"},{"issue":"10","key":"2600_CR33","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987\u2013996","journal-title":"N Engl J Med"},{"issue":"5","key":"2600_CR34","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","volume":"10","author":"R Stupp","year":"2009","unstructured":"Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459\u2013466","journal-title":"Lancet Oncol"},{"issue":"12","key":"2600_CR35","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1212\/WNL.0b013e31822f02e1","volume":"77","author":"M Weller","year":"2011","unstructured":"Weller M, Gorlia T, Cairncross JG et al (2011) Prolonged survival with valproic acid use in the EORTC\/NCIC temozolomide trial for glioblastoma. Neurology 77(12):1156\u20131164","journal-title":"Neurology"},{"issue":"1","key":"2600_CR36","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/PPO.0b013e318243f6c9","volume":"18","author":"M Weller","year":"2012","unstructured":"Weller M, Stupp R, Hegi M, Wick W (2012) Individualized targeted therapy for glioblastoma: fact or fiction? Cancer J 18(1):40\u201344","journal-title":"Cancer J"},{"issue":"5","key":"2600_CR37","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1056\/NEJMra0708126","volume":"359","author":"PY Wen","year":"2008","unstructured":"Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359(5):492\u2013507","journal-title":"N Engl J Med"},{"issue":"11","key":"2600_CR38","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1038\/sj.bjc.6605642","volume":"102","author":"P Workman","year":"2010","unstructured":"Workman P, Aboagye EO, Balkwill F et al (2010) Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102(11):1555\u20131577","journal-title":"Br J Cancer"},{"issue":"1","key":"2600_CR39","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nrd1930","volume":"5","author":"CB Yoo","year":"2006","unstructured":"Yoo CB, Jones PA (2006) Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5(1):37\u201350","journal-title":"Nat Rev Drug Discov"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-018-2600-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-018-2600-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-018-2600-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,14]],"date-time":"2022-08-14T04:06:55Z","timestamp":1660450015000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-018-2600-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,9]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["2600"],"URL":"https:\/\/doi.org\/10.1007\/s00432-018-2600-1","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,9]]},"assertion":[{"value":"4 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All applicable international, national, and\/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}